Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mesenchymal stromal cells.

Armand Keating1

  • 1Princess Margaret Hospital/Ontario Cancer Institute, Faculty of Medicine and Institute for Biomaterials and Biomedical Engineering, University of Toronto, ON, Canada. armand.keating@uhn.on.ca

Current Opinion in Hematology
|October 21, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intraperitoneal administration of NK-92 improves survival in xenografts of early and established ovarian cancer models.

PloS one·2026
Same author

IID 2025: Physical protein interaction data with detection types, co-purified protein sets, molecular docking, and immune cell networks.

Nucleic acids research·2025
Same author

A molecular systems architecture of the mesenchymal stromal cell microenvironment.

Stem cells (Dayton, Ohio)·2025
Same author

Reduced-intensity conditioning in LV-mediated gene therapy for Fabry disease targeting HSPCs.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Mesenchymal stromal cells: an update.

Current opinion in hematology·2025
Same author

Beyond maximum grade: tolerability of immunotherapies, cellular therapies, and targeted agents in haematological malignancies.

The Lancet. Haematology·2025
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Recent advances in mesenchymal stem cells (MSCs) reveal their potential in cell therapy. Their immunosuppressive and nonimmunogenic properties are key for treating conditions like graft-versus-host disease.

Area of Science:

  • Cell Biology
  • Immunology
  • Regenerative Medicine

Background:

  • Mesenchymal stem cells (MSCs), also known as multipotent mesenchymal stromal cells, have garnered significant attention.
  • Recent advancements have dramatically expanded our understanding of MSC biology and properties.

Purpose of the Study:

  • To review the timely and relevant topic of mesenchymal stem cells.
  • To highlight the expanding knowledge and potential clinical impact of MSCs.

Main Methods:

  • Review of recent scientific literature on mesenchymal stem cells.
  • Analysis of proposed nomenclature and definitions for MSCs.
  • Evaluation of studies defining rapidly dividing cell populations within MSCs.

Main Results:

Related Experiment Videos

  • Standardized nomenclature and definitions for mesenchymal stromal cells have been proposed.
  • The ability of MSCs to exhibit multilineage differentiation characteristics has been extended.
  • The mechanisms underlying MSC immunosuppression and nonimmunogenicity have been elucidated, with implications for graft-versus-host disease.
  • Tissue repair via MSCs may involve paracrine mechanisms rather than solely transdifferentiation, particularly in the myocardium.

Conclusions:

  • Mesenchymal stromal cells are crucial for supporting hematopoiesis.
  • MSCs can differentiate into mesenchymal and non-mesenchymal lineages in vitro.
  • Their capacity to suppress alloresponses and their nonimmunogenic nature suggest significant potential in cell therapy applications.